Verthermia Heatt to Treat

What Verthermia Heatt to Treat does

Verthermia (legal entity: Verthermia Acquisitions Inc., a Nevada-incorporated private company founded in 2012, headquartered in Henderson NV with treatment operations in Dallas, TX) has developed and commercialized HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy), a whole-body hyperthermia procedure that targets advanced-stage cancer and chronic Lyme disease. The HEATT procedure assembles FDA-approved heart-lung machine and dialysis components—including the patent-pending CoreHFC™ device—into a proprietary external circuit that withdraws a patient's blood, heats it externally, and returns it to the body via the right heart, raising core body temperature to 42°C (107.6°F) for 120 minutes while conducting charcoal-filtration dialysis to normalize fluids, electrolytes, and pH. The system is protected by four issued US patents (with two pending US applications and one PCT international application), and Verthermia has completed FDA Phase 1 clinical trials in ovarian and lung cancer, with the ovarian trial reporting 21.2-month median overall survival versus 8.9 months expected and 80% of patients exceeding predicted survival.

The company delivers HEATT as a treatment service exclusively at First Baptist Medical Center in Dallas, with typical patient hospital stays of 3–4 days and per-cycle pricing arranged via consultation rather than published rates. Its go-to-market is sales-led and inside-sales driven—patient acquisition runs through HubSpot scheduling, dedicated phone lines, medical provider referrals, content marketing (blog and YouTube testimonials), and direct outreach to advanced cancer patients who have exhausted conventional surgery, radiation, chemotherapy, and immunotherapy options. Primary customer segments are advanced/Stage IV cancer patients (with indication-specific pages for ovarian, breast, colon, and lung cancer), with secondary applications in pancreatic cancer and Lyme disease treated with antibiotic adjunct therapy. Verthermia is privately held, operates with 1–10 employees, has raised approximately $2.03 million in disclosed outside funding across two rounds (2013 and 2021), and is led by CEO Mitchel K. May alongside a credentialed clinical leadership team including a cardiothoracic surgeon/CMO, a perfusionist/CSO, and a Cornell-trained nephrologist/CCO, supported by an advisory board drawn from Memorial Sloan Kettering, Cleveland Clinic, Mount Sinai, Harvard/Massachusetts General/Dana-Farber, and Allegheny Health Network.

Name

Verthermia Heatt to Treat

Legal name

Verthermia Acquisitions INC

Website

https://verthermia.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Verthermia (Verthermia Acquisitions Inc.) is a private medical technology company that delivers HEATT® whole-body hyperthermia therapy—circulating a patient's externally heated blood at 42°C for 120 minutes—to advanced-stage cancer patients and chronic Lyme disease patients at a single facility at First Baptist Medical Center in Dallas, TX.

Ownership category

akta.pro rank

Product category

Whole-Body Hyperthermia Treatment

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)

akta.pro primary industry

Hot/Cold Therapy Services (Cryotherapy/Ice Baths) (HSALAFAH)

akta.pro secondary industry

Hot/Cold Contrast Therapy (Hot Tubs, Plunge Pools & Hydrotherapy) (HSADAKAD)

Keywords

• Whole-body hyperthermia
• Cancer thermotherapy
• Oncology treatment services
• Lyme disease therapy
• Extracorporeal tumor therapy

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. HEATT Treatment Services: Medical treatment services providing whole-body hyperthermia therapy for cancer patients. Treatment involves multiple day hospital stays and is performed at First Baptist Medical Center. Revenue generated through per-treatment cycle billing.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Verthermia provides HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy), a whole-body hyperthermia procedure that circulates a patient's blood through an external FDA-approved circuit, heating it to 42°C (107.6°F) for two hours to target cancer cells. The procedure is performed at First Baptist Medical Center in Dallas, Texas and is also applied as a treatment protocol for Lyme disease using elevated body temperature combined with antibiotic therapy.

Product overview

Verthermia offers HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy) as its core treatment product, a whole-body hyperthermia procedure that heats patient blood to 42°C using the proprietary CoreHFC™ device. The treatment is indicated for multiple cancer types including ovarian, breast, colon, and lung cancer, as well as Lyme disease. HEATT therapy works by circulating heated blood through an external FDA-approved circuit while normalizing fluids, electrolytes, and pH balance through dialysis, directly targeting cancer cells that cannot tolerate elevated temperatures. The company also provides disease-specific treatment protocols and has completed FDA Phase 1 clinical trials demonstrating safety and efficacy.

Differentiator

Problem solved

Functional benefit

Products and services

• HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy)

Quantifiable outcome

• Median survival increased from 8.9 months expected to 21.2 months actual for ovarian cancer patients (80% of trial patients exceeded predicted survival)
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• First Baptist Medical CentercoreImplementation/ SI/ Consulting PartnerTreatment facility where all HEATT procedures are performed. Located in Dallas, Texas. The operating room at First Baptist Medical Center serves as the primary treatment site, with recovery room care included as part of the HEATT treatment process. The facility provides a state-of-the-art environment for patient care.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pyrexar Medical: Hyperthermia medical device manufacturer (formerly BSD Medical) that produces systems for treating cancer with localized and regional hyperthermia. Directly competes with Verthermia in the oncology hyperthermia category with overlapping technology approach.
• Oncotherm: German manufacturer of regional deep hyperthermia devices used as an adjunct to chemo/radiation in oncology. Competes with Verthermia in the cancer hyperthermia modality, although Oncotherm focuses on regional rather than whole-body heating.
• Celsius42: German developer of whole-body hyperthermia systems for oncology and other indications. The most direct technical comparable to HEATT given its whole-body heating approach for cancer.
• Dr. Sennewald Medizintechnik GmbH: German medical device company specializing in hyperthermia systems for cancer treatment. Operates in the same oncology hyperthermia space as Verthermia with comparable clinical positioning.

Emerging players

• Hippocrates Health Institute: Alternative wellness and chronic-disease clinic offering whole-body hyperthermia among other modalities. Comparable as a niche operator delivering hyperthermia-based protocols to self-directed patients.
• Hope4Cancer: Alternative cancer treatment center that incorporates whole-body hyperthermia into its protocols. Comparable as a competing destination clinic for advanced-stage patients seeking non-standard therapies.
• Burzynski Clinic: Long-running alternative oncology clinic offering non-mainstream treatments to late-stage cancer patients. Comparable as a destination provider targeting the same exhausted-treatment patient segment that Verthermia addresses.

Broad incumbents

• City of Hope: One of the largest US comprehensive cancer centers (absorbing CTCA's clinical operations). Relevant as the dominant mainstream oncology provider against which Verthermia's niche last-resort offering must compete for advanced-stage patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@VerthermiaHEATT

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verthermia Heatt to Treat